Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Southern Kuzbass reported for 9 months of 2023 by RAS

10/20/23 UKUZ

LSR doubled the volume of real estate sales

10/20/23 LSRG

Board of Directors of Kuznetskiy Bank recommended that dividends be paid for 9 months 2023

10/20/23 KUZB

Chizhik went to Siberia

10/20/23 FIVE

UWC may issue additional shares at ₽9.3 per share

10/20/23 UWGN

Seligdar increased gold sales by 50%

10/20/23 SELG

Citigroup announced a quarterly dividend

10/20/23 C

Johnson & Johnson announced a quarterly dividend

10/20/23 JNJ

Board of Directors of Positive Technologies Group recommended that dividends be paid for 9 months 2023

10/19/23 POSI

Rostelecom creates national cybersecurity centers

10/19/23 RTKM